Join
Live feed
·
PRReleasevia Quantisnow
Alterity Therapeutics Limited logo

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

ByQuantisnow·Wall Street's wire, on your screen.
ATHE· Alterity Therapeutics Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATHE (Alterity Therapeutics Limited) and more on Quantisnow.